/GNPX
GNPX Stock - Genprex, Inc.
Healthcare|BiotechnologyNASDAQ
$2.13-1.84%
$0.04 (-1.84%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GNPX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.11 – $2.15
TARGET (TP)$2.45
STOP LOSS$1.96
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.76
52W High$55.00
52W Low$2.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-6,693 | $-15,004 | $-25,575 | $-22,534 | $-22,777 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-21,174,167 | $-31,075,570 | $-23,830,719 | $-20,670,102 | $-17,961,581 |
| Net Income | $-21,111,163 | $-30,860,461 | $-23,740,621 | $-20,664,969 | $-17,942,770 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-266.95 | $-1129.00 | $-990.00 | $-877.50 | $-1009.00 |
Company Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GNPXBeat Rate
17%
Last 18 quarters
Avg Surprise
-1172.3%
EPS vs Estimate
Beats / Misses
3/15
Last 12 quarters
Latest EPS
$-5.00
Q4 2025
EPS Surprise History
Q1 24
-0.8%
$-3.96vs$-3.93
Q2 24
-45.3%
$-3.69vs$-2.54
Q3 24
-30.4%
$-3.00vs$-2.30
Q4 24
-8.8%
$-1.23vs$-1.13
Q2 25
-40.2%
$-1.15vs$-0.82
Q2 25
+68.3%
$-0.26vs$-0.82
Q3 25
+59.5%
$-8.50vs$-21.00
Q4 25
+60.0%
$-5.00vs$-12.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-12.50 | $-5.00 | +60.0% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-21.00 | $-8.50 | +59.5% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.82 | $-0.26 | +68.3% | ✓ BEAT |
Q2 2025 | Apr 7, 2025 | $-0.82 | $-1.15 | -40.2% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.13 | $-1.23 | -8.8% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-2.30 | $-3.00 | -30.4% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-2.54 | $-3.69 | -45.3% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-3.93 | $-3.96 | -0.8% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.11 | $-5.20 | -4627.3% | ✗ MISS |
Q3 2023 | Aug 21, 2023 | $-4.80 | $-6.00 | -25.0% | ✗ MISS |
Q2 2023 | May 22, 2023 | $-4.80 | $-7.60 | -58.3% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-5.20 | $-6.00 | -15.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.12 | $-5.20 | -4233.3% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-4.00 | $-4.40 | -10.0% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-3.60 | $-4.80 | -33.3% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.09 | $-4.80 | -5233.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $-2.80 | — | — |
Q3 2021 | Aug 13, 2021 | $-0.13 | $-3.20 | -2361.5% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-0.12 | $-5.60 | -4566.7% | ✗ MISS |
Latest News
Genprex Reports Early Success For Its New Gene Therapy In Advanced Lung Cancer Trial
📈 PositiveBenzinga•Nov 24, 2025, 12:17 PM
Genprex Announces US Patent For Reqorsa Gene Therapy In Combination With PD-L1 Antibodies In Cancer Treatment
📈 PositiveBenzinga•Nov 18, 2025, 12:06 PM
Genprex Secures European Patent Office Intent To Grant Patent For Reqorsa Gene Therapy With PD-1 Antibodies, Expanding Global Cancer Treatment IP Portfolio
📈 PositiveBenzinga•Nov 4, 2025, 12:06 PM
Genprex Announces $10M ATM Registered Direct Offering Of 377,780 Shares Of Common Stock At $9.00 Per Share
➖ NeutralBenzinga•Oct 28, 2025, 03:25 PM
Genprex Said The Combination Of Reqorsa Gene Therapy (Quaratusugene Ozeplasmid) And An ALK Inhibitor Led To Longer Survival In The Mouse Model Of ALK-EML4 Positive Non-small Cell Lung Cancer
📈 PositiveBenzinga•Oct 28, 2025, 11:14 AM
Genprex shares are trading lower after the company announced a registered direct offering up to $8.1 million.
📉 NegativeBenzinga•Oct 23, 2025, 03:23 PM
Genprex Announces Registered Direct Offering Up To $8.1M; 243,622 Shares At $11.21/Share
➖ NeutralBenzinga•Oct 23, 2025, 12:17 PM
Genprex To Present Positive Preclinical Data At 2025 Aacr-nci-erotc International Conference On Molecular Targets And Cancer Therapeutics In Boston
📈 PositiveBenzinga•Oct 23, 2025, 11:05 AM
Genprex shares are trading lower after the company implemented previously disclosed 1-for-50 reverse stock split, reducing outstanding shares to 1,004,326.
📉 NegativeBenzinga•Oct 21, 2025, 05:18 PM
Genprex Implements Previously Disclosed 1-For-50 Reverse Stock Split, Reducing Outstanding Shares To 1,004,326
📉 NegativeBenzinga•Oct 21, 2025, 03:04 PM
Genprex Research Collaborators To Present At 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
➖ NeutralBenzinga•Oct 14, 2025, 11:03 AM
Genprex Secures U.S. And EU Patent Allowances For REQORSA Gene Therapy In Combination With PD-1/PD-L1 Inhibitors; Earliest Expiry 2037
📈 PositiveBenzinga•Aug 18, 2025, 01:32 PM
Frequently Asked Questions about GNPX
What is GNPX's current stock price?
Genprex, Inc. (GNPX) is currently trading at $2.13 per share. The stock has moved -1.84% today.
What is the analyst price target for GNPX?
No analyst price targets are currently available for this stock.
What sector is Genprex, Inc. in?
Genprex, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GNPX's market cap?
Genprex, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does GNPX pay dividends?
No, Genprex, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
BIVI
BioVie Inc.
$1.41
Mkt Cap: $0.0B
CERO
CERo Therapeutics Holdings, Inc.
$0.10
Mkt Cap: $0.0B
CMMB
Chemomab Therapeutics Ltd.
$1.89
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.79
Mkt Cap: $0.0B
TOVX
Theriva Biologics, Inc.
$0.19
Mkt Cap: $0.0B
Explore stocks similar to GNPX for comparison